GlassScriptPhysician profile
Jose C De Hoyos
NPI 1689600850
$4,097.47
in general payments reported to CMS, 2019-2025
33 companies · $1,358 in 2025
The $1,358 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $143 · 2022: $138 · 2023: $452 · 2024: $1,143 · 2025: $1,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,933 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,932.89 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $554.72 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $536.46 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $381.89 | 2019-2025 | |
| Abiomed | $363.77 | 2019-2025 | Impella |
| Abbott Laboratories | $337.17 | 2024-2025 | Cardiomems, Jot Dx, Ensite Precision |
| Amgen INC. | $280.46 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $232.83 | 2019-2025 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $143.78 | 2023-2025 | Farxiga, Brilinta |
| Shockwave Medical, INC | $138.32 | 2022 | |
| Sanofi-Aventis U.S. LLC | $97.27 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $97.05 | 2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $94.17 | 2025 | Amvuttra |
| Philips North America LLC | $90.83 | 2023-2025 | Azurion 7 M20 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.64 | 2024-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $87.18 | 2019-2024 | Xarelto |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $79.31 | 2024 | Corevalve Evolut R |
| Bayer Healthcare Pharmaceuticals INC. | $48.56 | 2024-2025 | |
| Novo Nordisk INC | $48.48 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $47.18 | 2023 | Verquvo |
| Ge Healthcare | $43.02 | 2023-2025 | |
| Siemens Medical Solutions USA, INC. | $40.04 | 2023-2025 | |
| Lundbeck LLC | $33.97 | 2019 | |
| Titan Surgical Group, LLC | $33.86 | 2025 | |
| Scpharmaceuticals INC. | $33.63 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $22.51 | 2024 | Arcalyst |
| United Therapeutics Corporation | $21.01 | 2019 | |
| Amarin Pharma, INC. | $20.00 | 2019 | |
| Atricure, INC. | $19.85 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $19.16 | 2024 | |
| Kestra Medical Technology Services, INC. | $19.03 | 2025 | Assure Wcd |
| Polynovo North America LLC | $18.96 | 2025 | Novosorb Btm |
| Gilead Sciences, INC. | $13.33 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose De Hoyos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.